This inventor holds 3 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Chemo-Sero-Therapeutic Research Institute. Active years: 2005-2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Kikuchi-gun, JP (2005)
- Kumamoto-ken, JP (2006 - 2008)
Company Filing History:
Years Active: 2005-2008
Title: Kaori Teshima: Innovator in Hemostatic Compositions
Introduction
Kaori Teshima is a prominent inventor based in Kumamoto, Japan. She has made significant contributions to the field of pharmaceutical compositions, particularly in the development of hemostatic agents. With a total of 3 patents, her work focuses on innovative solutions for treating bleeding disorders.
Latest Patents
Teshima's latest patents include a pharmaceutically stable hemostatic composition. This novel composition features a mixed solution of activated blood coagulation factor VII (FVIIa) and blood coagulation factor X (FX) maintained at a pH ranging from 5.0 to 6.5. Additionally, she has developed medicinal compositions aimed at preventing and treating hemorrhagic diseases associated with thrombopathy. This pharmaceutical composition is designed for patients suffering from bleeding disorders caused by platelet dysfunction, providing a hemostatic effective amount of Factor VIII and/or von Willebrand Factor.
Career Highlights
Throughout her career, Teshima has worked with notable organizations, including the Chemo-Sero-Therapeutic Research Institute. Her innovative research has positioned her as a key figure in the development of hemostatic therapies.
Collaborations
Teshima has collaborated with esteemed colleagues such as Tatsuya Araki and Tomohiro Nakagaki. These partnerships have further enhanced her research and contributions to the field.
Conclusion
Kaori Teshima's work in hemostatic compositions showcases her dedication to advancing medical treatments for bleeding disorders. Her innovative patents and collaborations highlight her significant impact in the pharmaceutical industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile